BBB opening with focused ultrasound in nonhuman primates and Parkinson’s disease patients: Targeted AAV vector delivery and PET imaging
Authors:
- Javier BlesaJBJavier Blesa
- José A. Pineda-PardoJPJosé A. Pineda-Pardo
- Ken-Ichi InoueKIKen-Ichi Inoue
- Carmen Gasca-SalasCarmen Gasca-Salas
- Tiziano BalzanoTiziano Balzano
- Natalia López-González Del ReyNRNatalia López-González Del Rey
- Alejandro Reinares-SebastiánARAlejandro Reinares-Sebastián
- Noelia Esteban-GarcíaNENoelia Esteban-García
- Rafael Rodríguez-RojasRRRafael Rodríguez-Rojas
- María CiorragaMCMaría Ciorraga
- Marta del ÁlamoMÁMarta del Álamo
Top Cited Papers
Open Access
- 21 April 2023
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (16) , eadf4888
Abstract
Intracerebral vector delivery in nonhuman primates has been a major challenge. We report successful blood-brain barrier opening and focal delivery of adeno-associated virus serotype 9 vectors into brain regions involved in Parkinson’s disease using low-intensity focus ultrasound in adult macaque monkeys. Openings were well tolerated with generally no associated abnormal magnetic resonance imaging signals. Neuronal green fluorescent protein expression was observed specifically in regions with confirmed blood-brain barrier opening. Similar blood-brain barrier openings were safely demonstrated in three patients with Parkinson’s disease. In these patients and in one monkey, blood-brain barrier opening was followed by 18 F-Choline uptake in the putamen and midbrain regions based on positron emission tomography. This indicates focal and cellular binding of molecules that otherwise would not enter the brain parenchyma. The less-invasive nature of this methodology could facilitate focal viral vector delivery for gene therapy and might allow early and repeated interventions to treat neurodegenerative disorders.Keywords
This publication has 57 references indexed in Scilit:
- Disease duration and the integrity of the nigrostriatal system in Parkinson’s diseaseBrain, 2013
- Immune responses to AAV vectors: overcoming barriers to successful gene therapyBlood, 2013
- Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene TherapyHuman Gene Therapy Methods, 2013
- The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: A PET, histological and biochemical studyNeurobiology of Disease, 2012
- Temporary Disruption of the Blood–Brain Barrier by Use of Ultrasound and Microbubbles: Safety and Efficacy Evaluation in Rhesus MacaquesCancer Research, 2012
- Adeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman PrimatesHuman Gene Therapy, 2012
- Systemic Gene Delivery in Large Species for Targeting Spinal Cord, Brain, and Peripheral Tissues for Pediatric DisordersMolecular Therapy, 2011
- Preclinical Differences of Intravascular AAV9 Delivery to Neurons and Glia: A Comparative Study of Adult Mice and Nonhuman PrimatesMolecular Therapy, 2011
- AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trialThe Lancet Neurology, 2011
- Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsHuman Gene Therapy, 2010